Methods and biomarker for evaluating cancer metastasis, pharmaceutical composition for inhibiting cancer metastasis, and method for analyzing secretome
US9194005B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 17, 2013 |
| Grant date | Nov 24, 2015 |
| Priority date | — |
| Expiry date | Oct 12, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2570/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to methods and biomarker for evaluating cancer metastasis, pharmaceutical composition for inhibiting cancer metastasis, and method for analyzing secretome. By combining a hollow fiber cartridge (HFC) culture system with quantitative proteomics technology, cancer metastasis-related secrectomes can be found. Furthermore, this is the first time to use PARK7 as a biomarker for judging the process of non-small cell lung cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.